Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene study aims to predict stroke outcomes

NCT ID NCT07269288

Knowledge-focused Sponsor: Peking University Aerospace Center Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how changes in the GGCX gene relate to recovery after an ischemic stroke. Researchers will collect blood samples from 1,500 stroke patients and follow them for 12 months to track strokes, bleeding, and deaths. The goal is to understand if this gene can help predict who will have better or worse outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict stroke outcomes and personalize treatment based on a patient's genes.
What could go wrong
This is an observational study, not a treatment trial. It may find no clear link between the GGCX gene and stroke prognosis, or results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will be conducted in six hospitals (centers) across the country, namely Xi'an Jiaotong University First Affiliated Hospital, Shandong Weifang Second People's Hospital, Shandong Linshu People's Hospital, Hunan Second People's Hospital (Hunan Brain Hospital), and Nantong First People's Hospital.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria (1) Inclusion Criteria for Acute Ischemic Stroke Patients: 1. Aged between 18 and 85 years. 2. Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)). 3. Acute onset, with symptoms occurring within 72 hours and being the first episode. 4. Voluntary participation with signed informed consent. (2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history). * Exclusion Criteria (1) Exclusion Criteria for Healthy Controls: 1. Patients with cerebrovascular diseases occurring within 72 hours. 2. Pregnant or lactating patients. (2) Exclusion Criteria for Acute Ischemic Stroke Patients: 1. Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients. 2. Patients with coagulation disorders or other hematologic diseases. 3. Patients with severe cardiovascular, pulmonary, or hepatic diseases. 4. Renal dysfunction. 5. Cancer patients. 6. Patients with active gastric ulcers or gastric bleeding. 7. Pregnant or lactating patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University Aerospace Center Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.